Pages that link to "Item:Q4521868"
From MaRDI portal
The following pages link to On meta-analytic assessment of surrogate outcomes (Q4521868):
Displaying 16 items.
- Flexible surrogate marker evaluation from several randomized clinical trials with continuous endpoints, using R and SAS (Q1020068) (← links)
- Simplified modeling strategies for surrogate validation with multivariate failure-time data (Q2445595) (← links)
- The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials (Q2475730) (← links)
- Statistical evaluation of surrogate endpoints with examples from cancer clinical trials (Q2792764) (← links)
- Surrogate measures and consistent surrogates (Q2861938) (← links)
- Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling (Q2894010) (← links)
- Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time (Q2894011) (← links)
- Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials (Q3076045) (← links)
- The Evaluation of Multiple Surrogate Endpoints (Q3078684) (← links)
- Principal Stratification in Causal Inference (Q3078899) (← links)
- Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints (Q3445296) (← links)
- On the relationship between the causal‐inference and meta‐analytic paradigms for the validation of surrogate endpoints (Q3465713) (← links)
- On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm (Q3637000) (← links)
- Multivariate meta‐analysis with an increasing number of parameters (Q5348688) (← links)
- Predictive probability of success using surrogate endpoints (Q6625585) (← links)
- Optimizing and evaluating biomarker combinations as trial-level general surrogates (Q6625926) (← links)
